Insulin Glargine (Lantus ®) and a Possible Link with Cancer (October 2017)
Position Statement Download the full version of the ‘ADS Position Statement on Insulin Glargine (Lantus®) and a Possible Link with Cancer – PDF (Posted: October, 2017)
Position Statement Download the full version of the ‘ADS Position Statement on Insulin Glargine (Lantus®) and a Possible Link with Cancer – PDF (Posted: October, 2017)
Authors: Mervyn Kyi, Barbora Paldus, Natalie Nanayakkara, Michael Bennett, Rebecca Johnson, Catherine Meehan, Peter Colman Summary In 2015 the Australian Diabetes Society commissioned a working group to review and revise
Summary These guidelines have been developed by an ADS working group and are primarily intended to provide assistance for those practitioners whose primary focus is not diabetes or who do not have the support
Summary The 2012 ADS Guidelines for Routine Glucose Control in Hospital have been developed over the last year, and cover a range of areas including general hospital wards, myocardial infarction, stroke, steroid-induced
The National evidence‐based clinical care guidelines for type 1 diabetes in children, adolescents and adults is the first national evidence‐based clinical care guideline for type 1 diabetes across the lifespan. This document was developed by an Expert Advisory Group (EAG) representing specialist societies and organisations, with the active participation of consumer groups and the community.
Summary The Australian Diabetes Society has produced a Position Statement regarding the individualization of HbA1c targets, for adults with diabetes mellitus. This has been published in the Medical Journal of
Posted: May, 2007You can read the MJA article online.
For all enquiries:
145 Macquarie Street,
Sydney, NSW, 2000
Acknowledgement of Country
The Australian Diabetes Society acknowledges the Traditional Custodians of the lands upon which we live, learn and work.
We pay our respects to Elders both past, present and future.
Design by Aptly